1.Usefulness of Rigid Bronchoscopic Intervention Using Argon Plasma Coagulation for Central Airway Tumors.
Bo Ram LEE ; In Jae OH ; Ho Sung LEE ; Hee Jung BAN ; Kyu Sik KIM ; Yu Il KIM ; Sung Chul LIM ; Young Chul KIM ; Yong Wook PARK ; Yong Soo KWON
Clinical and Experimental Otorhinolaryngology 2015;8(4):396-401
OBJECTIVES: Argon plasma coagulation (APC) is a noncontact form of electrocautery that utilizes ionized argon as the electrical current. A rigid bronchoscopic use of APC for the management of central airway obstruction could be safe and rapidly effective. This study evaluated the usefulness of rigid bronchoscopy with APC for the management of central airway obstructions due to benign or malignant tumors. METHODS: Twenty patients with obstructing central airway tumors were retrospectively reviewed from February 2008 to February 2013 at Chonnam National University Hospital. All patients received rigid bronchoscopic tumor removal under general anesthesia. APC was applied before and after tumor removal. RESULTS: The median age of patients was 59 years (interquartile range [IQR], 51 to 67 years) and 70% were female. The causes of airway obstruction included malignancy (n=8) and benign tumor (n=12). Airway tumors comprised intraluminal lesions (n=11, 55%) and mixed intraluminal/extraluminal lesions (n=9, 45%). The median tumor size was 15 mm (IQR, 10 to 18 mm). The median degree of airway obstruction was significantly reduced after intervention (90% [IQR, 88% to 96%] vs. 10% [IQR, 0% to 20%], P<0.001). The median American Thoracic Society dyspnea grade (3 [IQR, 1 to 4] vs. 1 [IQR, 0 to 1], P<0.001) and forced expiratory volume in one second (1.03 L [IQR, 0.52 to 1.36 L] vs. 1.98 L [IQR, 1.57 to 2.64 L], P=0.004) were significantly improved after intervention. There were no procedure-related acute complications and deaths. CONCLUSION: Rigid bronchoscopy with APC is an effective and safe procedure to alleviate central airway obstruction caused by tumors.
Airway Obstruction
;
Anesthesia, General
;
Argon Plasma Coagulation*
;
Argon*
;
Bronchoscopy
;
Dyspnea
;
Electrocoagulation
;
Female
;
Forced Expiratory Volume
;
Humans
;
Jeollanam-do
;
Retrospective Studies
2.The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application.
Myung Jin BAN ; Jae Hong PARK ; Jae Wook KIM ; Ki Nam PARK ; Jae Yong LEE ; Hee Kyung KIM ; Seung Won LEE
Clinical and Experimental Otorhinolaryngology 2017;10(4):349-356
OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. RESULTS: FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P < 0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. CONCLUSION: Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring.
Acoustics
;
Animals*
;
Cicatrix*
;
Collagen
;
Dysphonia
;
Fibroblast Growth Factor 2
;
Fibroblast Growth Factors*
;
Fibroblasts*
;
Follow-Up Studies
;
Granuloma
;
Humans
;
Hyaluronic Acid
;
Korea
;
Ligases
;
Matrix Metalloproteinase 2
;
Models, Animal*
;
Procollagen
;
Prospective Studies
;
Real-Time Polymerase Chain Reaction
;
RNA, Messenger
;
Specific Gravity
;
Tertiary Care Centers
;
Vocal Cords*
;
Voice
;
Voice Quality
3.Validation of Five Cardinal Symptoms Used for Stroke Awareness Campaign.
Wook Joo KIM ; Youngchai KO ; Jung Hyun PARK ; Byeolnim BAN ; Moon Ku HAN ; Yong Jin CHO ; Hee Joon BAE
Journal of the Korean Neurological Association 2013;31(1):15-20
BACKGROUND: For the improvement in stroke care, we have campaigned for stroke warning signs and its symptoms. However, few reports on the validation of symptom selection in the campaign have been published till now. METHODS: Based on the prospective stroke registry, patients were identified, who were hospitalized with stroke within 7 days from the stroke onset and had relevant lesions on their brain images. One presenting symptom was selected in each patient through review of electronic medical records by an investigator, and those collected symptoms were classified into 5 symptom categories or the unclassified. Those 5 symptom categories were developed and are being used in the stroke awareness campaign in 2009 by the Korean Stroke Society (KSS). RESULTS: A total of 3027 patients (age, 66.57+/-12.6 years; male, 58.2%) were enrolled in our study. The rate of frequency of each categorized symptom was 54.9% for unilateral numbness or weakness, 27.5% for confusion or speech disturbance, 2.8% for visual disturbance, 10.5% for dizziness or gait disturbance, 2.3% for severe headache, and 2.0% for the unclassified. Ninety-eight percent of stroke patients were classified into one of the 5 symptom categories. Confusion or speech disturbance was associated with the shorter pre-hospital delay, whereas dizziness or gait disturbance with the longer delay. Dizziness was the most frequent symptom in TIA, and so was severe headache in hemorrhagic stroke. CONCLUSIONS: Our study shows that the 5 stroke warning symptoms of the KSS campaign represent well the presenting symptoms of Korean patients with acute stroke or TIA.
Brain
;
Dizziness
;
Electronic Health Records
;
Gait
;
Headache
;
Humans
;
Hypesthesia
;
Male
;
Prospective Studies
;
Research Personnel
;
Stroke
4.RNA-Seq De Novo Assembly and Differential Transcriptome Analysis of Korean Medicinal Herb Cirsium japonicum var. spinossimum
Neha Samir ROY ; Jung A KIM ; Ah Young CHOI ; Yong Wook BAN ; Nam Il PARK ; Kyong Cheul PARK ; Hee sun YANG ; Ik Young CHOI ; Soonok KIM
Genomics & Informatics 2018;16(4):e34-
Cirsium japonicum belongs to the Asteraceae or Compositae family and is a medicinal plant in Asia that has a variety of effects, including tumour inhibition, improved immunity with flavones, and antidiabetic and hepatoprotective effects. Silymarin is synthesized by 4-coumaroyl-CoA via both the flavonoid and phenylpropanoid pathways to produce the immediate precursors taxifolin and coniferyl alcohol. Then, the oxidative radicalization of taxifolin and coniferyl alcohol produces silymarin. We identified the expression of genes related to the synthesis of silymarin in C. japonicum in three different tissues, namely, flowers, leaves, and roots, through RNA sequencing. We obtained 51,133 unigenes from transcriptome sequencing by de novo assembly using Trinity v2.1.1, TransDecoder v2.0.1, and CD-HIT v4.6 software. The differentially expressed gene analysis revealed that the expression of genes related to the flavonoid pathway was higher in the flowers, whereas the phenylpropanoid pathway was more highly expressed in the roots. In this study, we established a global transcriptome dataset for C. japonicum. The data shall not only be useful to focus more deeply on the genes related to product medicinal metabolite including flavolignan but also to study the functional genomics for genetic engineering of C. japonicum.
Asia
;
Asteraceae
;
Cirsium
;
Dataset
;
Estrone
;
Flavones
;
Flowers
;
Gene Expression Profiling
;
Genetic Engineering
;
Genomics
;
Humans
;
Plants, Medicinal
;
Sequence Analysis, RNA
;
Silymarin
;
Transcriptome
5.Analysis of genome variants in dwarf soybean lines obtained in F6 derived from cross of normal parents (cultivated and wild soybean)
Neha Samir ROY ; Yong-Wook BAN ; Hana YOO ; Rahul Vasudeo RAMEKAR ; Eun Ju CHEONG ; Nam-Il PARK ; Jong Kuk NA ; Kyong-Cheul PARK ; Ik-Young CHOI
Genomics & Informatics 2021;19(2):e19-
Plant height is an important component of plant architecture and significantly affects crop breeding practices and yield. We studied DNA variations derived from F5 recombinant inbred lines (RILs) with 96.8% homozygous genotypes. Here, we report DNA variations between the normal and dwarf members of four lines harvested from a single seed parent in an F6 RIL population derived from a cross between Glycine max var. Peking and Glycine soja IT182936. Whole genome sequencing was carried out, and the DNA variations in the whole genome were compared between the normal and dwarf samples. We found a large number of DNA variations in both the dwarf and semi-dwarf lines, with one single nucleotide polymorphism (SNP) per at least 3.68 kb in the dwarf lines and 1 SNP per 11.13 kb of the whole genome. This value is 2.18 times higher than the expected DNA variation in the F6 population. A total of 186 SNPs and 241 SNPs were discovered in the coding regions of the dwarf lines 1282 and 1303, respectively, and we discovered 33 homogeneous nonsynonymous SNPs that occurred at the same loci in each set of dwarf and normal soybean. Of them, five SNPs were in the same positions between lines 1282 and 1303. Our results provide important information for improving our understanding of the genetics of soybean plant height and crop breeding. These polymorphisms could be useful genetic resources for plant breeders, geneticists, and biologists for future molecular biology and breeding projects.
6.Analysis of genome variants in dwarf soybean lines obtained in F6 derived from cross of normal parents (cultivated and wild soybean)
Neha Samir ROY ; Yong-Wook BAN ; Hana YOO ; Rahul Vasudeo RAMEKAR ; Eun Ju CHEONG ; Nam-Il PARK ; Jong Kuk NA ; Kyong-Cheul PARK ; Ik-Young CHOI
Genomics & Informatics 2021;19(2):e19-
Plant height is an important component of plant architecture and significantly affects crop breeding practices and yield. We studied DNA variations derived from F5 recombinant inbred lines (RILs) with 96.8% homozygous genotypes. Here, we report DNA variations between the normal and dwarf members of four lines harvested from a single seed parent in an F6 RIL population derived from a cross between Glycine max var. Peking and Glycine soja IT182936. Whole genome sequencing was carried out, and the DNA variations in the whole genome were compared between the normal and dwarf samples. We found a large number of DNA variations in both the dwarf and semi-dwarf lines, with one single nucleotide polymorphism (SNP) per at least 3.68 kb in the dwarf lines and 1 SNP per 11.13 kb of the whole genome. This value is 2.18 times higher than the expected DNA variation in the F6 population. A total of 186 SNPs and 241 SNPs were discovered in the coding regions of the dwarf lines 1282 and 1303, respectively, and we discovered 33 homogeneous nonsynonymous SNPs that occurred at the same loci in each set of dwarf and normal soybean. Of them, five SNPs were in the same positions between lines 1282 and 1303. Our results provide important information for improving our understanding of the genetics of soybean plant height and crop breeding. These polymorphisms could be useful genetic resources for plant breeders, geneticists, and biologists for future molecular biology and breeding projects.
7.Temozolomide-Associated Bronchiolitis Obliterans Organizing Pneumonia Successfully Treated with High-Dose Corticosteroid.
Tae Ok KIM ; In Jae OH ; Hyun Wook KANG ; Su Young CHI ; Hee Jung BAN ; Yong Soo KWON ; Kyu Sik KIM ; Yu Il KIM ; Sung Chul LIM ; Young Chul KIM
Journal of Korean Medical Science 2012;27(4):450-453
Temozolomide is an oral alkylating agent with clinical activity against glioblastoma multiforme (GM). It is generally well-tolerated and has few pulmonary side effects. We report a case of temozolomide-associated brochiolitis obliterans organizing pneumonia (BOOP) requiring very high-dose corticosteroid treatment. A 56-yr-old woman presented with a 2-week history of exertional dyspnea. For the treatment of GM diagnosed 4 months previously, she had undergone surgery followed by chemoradiotherapy, and then planned adjuvant chemotherapy with temozolomide. After the 1st cycle, progressive dyspnea was gradually developed. Chest radiograph showed diffuse patchy peribronchovascular ground-glass opacities in both lungs. Conventional dose of methylprednisolone (1 mg/kg/day) was begun for the possibility of BOOP. Although transbronchial lung biopsy findings were compatible with BOOP, the patient's clinical course was more aggravated until hospital day 5. After the dose of methylprednisolone was increased (500 mg/day for 5 days) radiologic findings were improved dramatically.
Antineoplastic Agents, Alkylating/*adverse effects/therapeutic use
;
Cryptogenic Organizing Pneumonia/*chemically induced/*drug therapy/radiography
;
Dacarbazine/adverse effects/*analogs & derivatives/therapeutic use
;
Dyspnea/etiology
;
Female
;
Glioblastoma/drug therapy/radiography
;
Glucocorticoids/*therapeutic use
;
Humans
;
Methylprednisolone/therapeutic use
;
Middle Aged
;
Tomography, X-Ray Computed
8.Influence of Diaphragmatic Mobility on Hypercapnia in Patients with Chronic Obstructive Pulmonary Disease.
Hyun Wook KANG ; Tae Ok KIM ; Bo Ram LEE ; Jin Yeong YU ; Su Young CHI ; Hee Jung BAN ; In Jae OH ; Kyu Sik KIM ; Yong Soo KWON ; Yu Il KIM ; Young Chul KIM ; Sung Chul LIM
Journal of Korean Medical Science 2011;26(9):1209-1213
A reduction in diaphragm mobility has been identified in patients with chronic obstructive pulmonary disease (COPD) and has been associated with a decline in pulmonary function parameters. However, little information exists regarding the potential role of diaphragm mobility on hypercapnia in COPD. A new method of assessing the mobility of the diaphragm, using ultrasound, has recently been validated. The purpose of the present study was to investigate the relationship between diaphragm mobility and pulmonary function parameters, as well as that between arterial blood gas values and diaphragm mobility, in COPD patients. Thirty seven COPD patients were recruited for pulmonary function test, arterial blood gas analysis and diaphragm mobility using ultrasound to measure the craniocaudal displacement of the left branch of the portal vein. There were significant negative correlations between diaphragmatic mobility and PaCO2 (r = -0.373, P = 0.030). Diaphragmatic mobility correlated with airway obstruction (FEV1, r = 0.415, P = 0.011) and with ventilatory capacity (FVC, r = 0.302, P = 0.029; MVV, r = 0.481, P = 0.003). Diaphragmatic mobility also correlated significantly with pulmonary hyperinflation. No relationship was observed between diaphragm mobility and PaO2 (r = -0.028, P = 0.873). These findings support a possibility that the reduction in diaphragm mobility relates to hypercapnia in COPD patients.
Aged
;
Airway Resistance/physiology
;
Carbon Dioxide/blood/physiology
;
Diaphragm/physiopathology/*ultrasonography
;
Female
;
Humans
;
Hypercapnia/complications/*physiopathology
;
Male
;
Middle Aged
;
Portal Vein
;
Pulmonary Disease, Chronic Obstructive/complications/*physiopathology/ultrasonography
;
Pulmonary Gas Exchange
;
Respiratory Muscles/physiopathology
9.Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer.
Hong Joon SHIN ; Tae Ok KIM ; Hyun Wook KANG ; Su Young CHI ; Hee Jung BAN ; Soo Ok KIM ; Yong Soo KWON ; In Jae OH ; Kyu Sik KIM ; Yu Il KIM ; Sung Chul LIM ; Young Chul KIM
Tuberculosis and Respiratory Diseases 2011;71(1):15-23
BACKGROUND: Gefitinib and erlotinib are useful, molecular targeted agents in patients with non-small-cell lung cancer (NSCLC) who failed previous chemotherapy. We compared the efficacy and toxicity of two drugs in patients with squamous cell lung cancer, most of whom are male smokers. METHODS: We retrospectively reviewed the clinical information on patients with NSCLC who were treated with gefitinib or erlotinib treatment at Chonnam National University Hwasun Hospital between July 2002 and November 2009. The overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were compared between the two drugs. RESULTS: A total of 182 (100 gefitinib vs. 82 erlotinib) of 584 patients treated by targeted agents had squamous histology. Of the 182 patients, 167 (91.7%) were male and 159 (87.4%) were smokers. The ORR and disease control rate (DCR) were 4.9% and 40.6%, and there was no significant difference between gefitinib and erlotinib (ORR, 5.0% vs 4.8%; p=0.970; DCR, 40.0% vs 41.4%; p=0.439). The median OS in the gefitinib group was 12.1 months, and that in the erlotinib was 12.7 months (hazard ratio [HR], 1.282; 95% confidence interval [CI], 0.771~2.134; p=0.339). The median PFS for the gefitinib group was 1.40 months, compared with 1.37 months for the erlotinib group (HR, 1.092; 95% CI, 0.809~1.474; p=0.564). Skin rash > or =grade 3 was more common in erlotinib (12.2%) than gefitinib (1.0%, p=0.003) groups. CONCLUSION: This retrospective study showed that the two drugs appear to have similar antitumor efficacy and toxicity except for skin rash.
Carcinoma, Squamous Cell
;
Disease-Free Survival
;
Exanthema
;
Humans
;
Lung
;
Lung Neoplasms
;
Male
;
Quinazolines
;
Retrospective Studies
;
Treatment Outcome
;
Erlotinib Hydrochloride
10.A Case of Ischemic Colitis Associated with Paclitaxel Loaded Polymeric Micelle (Genexol-PM(R)) Chemotherapy.
Choel Kyu PARK ; Hyun Wook KANG ; Tae Ok KIM ; Ho Seok KI ; Eun Young KIM ; Hee Jung BAN ; Byeong Kab YOON ; In Jae OH ; Yoo Deok CHOI ; Yong Soo KWON ; Yoo Il KIM ; Sung Chul LIM ; Young Chul KIM ; Kyu Sik KIM
Tuberculosis and Respiratory Diseases 2010;69(2):115-118
Paclitaxel has been widely used for treating many solid tumors. Although colonic toxicity is an unusual complication of paclitaxel-based chemotherapy, the reported toxicities include pseudomembranous colitis, neutropenic enterocolitis and on rare occasions ischemic colitis. Genexol-PM(R), which is a recently developed cremophor-free, polymeric micelle-formulated paclitaxel, has shown a more potent antitumor effect because it can increase the usual dose of paclitaxel due to that Genexol-PM(R) does not include the toxic cremophor compound. We report here on a case of a 57-year-old man with advanced non-small cell lung cancer and who developed ischemic colitis after chemotherapy with Genexol-PM(R) and cisplatin. He complained of hematochezia with abdominal pain on the left lower quadrant. Colonoscopy revealed diffuse mucosal hemorrhage and edema from the sigmoid colon to the splenic flexure. After bowel rest, he recovered from his symptoms and the follow-up colonoscopic findings showed that the mucosa was healing. Since then, he was treated with pemetrexed monotherapy instead of a paclitaxel compound and platinum.
Abdominal Pain
;
Carcinoma, Non-Small-Cell Lung
;
Cisplatin
;
Colitis, Ischemic
;
Colon
;
Colon, Sigmoid
;
Colon, Transverse
;
Colonoscopy
;
Edema
;
Enterocolitis, Neutropenic
;
Enterocolitis, Pseudomembranous
;
Follow-Up Studies
;
Gastrointestinal Hemorrhage
;
Glutamates
;
Guanine
;
Hemorrhage
;
Humans
;
Middle Aged
;
Mucous Membrane
;
Paclitaxel
;
Platinum
;
Polyethylene Glycols
;
Polymers
;
Pemetrexed